Immunological evaluation of a recombinant vaccine delivered with an analogous hyaluronic acid chitosan nanoparticle-hydrogel against Toxoplasma gondii in mice.
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND Toxoplasma gondii (T. gondii) is not only a threat to the public health but it also poses adverse impacts on the livestock industry. This study aimed to develop a recombinant vaccine composed of T. gondii microneme protein 6 (TgMIC6) and T. gondii rhoptry protein 18 (TgROP18).The vaccine was delivered with a novel vector, named analogous hyaluronic acid chitosan nanoparticle-hydrogel (AHACNP-HG) and its immune protection was evaluated. METHODS The recombinant MIC6 and ROP18 proteins were obtained by affinity chromatography and loaded onto AHACNP-HG by magnetic stirring. The characterizations of AHACNP-HG were investigated, including its structure, rheological property, nanoparticle size and zeta potential, its ability to release protein in vitro and toxicology in vivo. The immunological and anti-infection effects of AHACNP-HG/rMIC6/rROP18 were examined in the mice model. RESULTS AHACNP-HG presented a characteristic of composite system and possessed biosecurity with excellent protein control-release property. AHACNP-HG/rMIC6/rROP18 vaccine enhanced a mixed Th1/Th2 cellular immune response accompanied by an increased level of the cytokines, IFN-γ and IL-10. It also provoked a stronger humoral immune response. Additionally, after challenge with T. gondii tachyzoite, AHACNP-HG/rMIC6/rROP18 inoculation prolonged the survival time of mice. CONCLUSION Our data indicated that mixed rMIC6 and rROP18 induced strong immune response and played a certain protective role in cont…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Exploring modified chitosan-based gene delivery technologies for therapeutic advancements
Gholap, A. D., Kapare, H. S., Pagar, S., Kamandar, P. A., Bhowmik, D. D., Vishwakarma, N., Raikwar, S., Garkal, A., Mehta, T. A., Rojekar, S. V., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129581 · Cited by 83
Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases
Sinani, G., Sessevmez, M., & Şenel, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091201 · Cited by 33
Carboxymethyl Chitosan and Chitosan as a Bioactive Delivery System: A Review
Alemi, P. S., Mohamadali, M., Arab‐Ahmadi, S., Irani, S., & Sharifi, F. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2758 · Cited by 22
Chitosan non-particulate vaccine delivery systems
Masimov, R., & Wasan, E. K. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12921 · Cited by 30
In vivo immunological activity of chitosan-derived nanoparticles.
Xu, C., Xing, R., Liu, S., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130105 · Cited by 22
Animal vaccine revolution: Nanoparticle adjuvants open the future of vaccinology
Xu, S., Sun, C., Qian, T., Chen, Y., Dong, X., Wang, A., Zhang, Q., Ji, Y., Jin, Z., Liu, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113827 · Cited by 19
Hamdi, M., Sun, H., Pan, L., Wang, D., Sun, M., Zeng, Z., Li, S., Dong, Q., & Su, F. (2025) · European Polymer Journal · doi:10.1016/j.eurpolymj.2025.113882 · Cited by 15
Chitosan-based nanomaterials: Pioneering a review in veterinary medicine applications
Yang, K., Zhu, R., Bao, H., Xu, S., Gao, Y., Xue, Y., Wang, J., Wang, X., Pan, Y., Liang, H., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146011 · Cited by 9
Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications
Zhao, P., Yang, Y., Yu, L., Li, G., & Zhu, D. (2025) · Gels · doi:10.3390/gels11060468 · Cited by 7
“Similarly, a chitosan–hyaluronic acid composite hydrogel used to deliver a Toxoplasma gondii antigen elicited a 2.7-fold elevation in total IgG levels and a marked increase in IgG1 production, indicating a robust and sustained Th2-type humoral response [57].”
InfluentialSelf-citationZhang, T., Tian, Y.-W., Zhang, X., et al. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106871 · Cited by 5
Guo, X., Zhou, C., Cui, L.-L., Qiu, H.-J., Wang, Y., Fu, M., Liu, D.-A., Han, B., Zhou, H., & Zhou, D. (2024) · Acta Tropica · doi:10.1016/j.actatropica.2024.107302 · Cited by 4
Self-citationQadeer, A., Tharwat, M., Khan, M. Z., Juhász, A., & Alshanbari, F. A. (2026) · Veterinary Sciences · doi:10.3390/vetsci13050437 · Cited by 4
“Additional formulations—PLGA/chitosan-TgRPS2 [66]; AHACNP-HG hydrogel with MIC6/ROP18 [67]; PLGA-SAG1 with TLR ligands [63]; PLGA-GRA12 vs. GRA7 [68]; alginate-ES antigens [69]; chitosan-SAG1 with propranolol/naltrexone [70,71]— have all shown protective activity.”
Metadata
- Authors
- yu, L., Li, H., Liang, X., Sun, W., Zhuang, B., Cao, Y., Zhang, J., Wang, Y., & shen, J.
- Affiliations
- Anhui Medical University (CN)
- Anhui University (CN)
- Corresponding author
- yu, li
- Venue
- Microbial Pathogenesis
- Publisher
- Elsevier BV
- Published
- 2023
- ISSN
- 1556-5068 (ISSN-L)
- OpenAlex
- W4321844968
- Cited by
- 0
- References
- 0
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Locations
- SSRN Electronic Journal (acceptedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Toxoplasma gondii, toxoplasmosis, recombinant vaccine, nanoparticle vaccine delivery, Th1/Th2 immune response, cytokine production, humoral immune response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.